Alexander Drilon MD
@alexdrilon
Chief, Early Drug Development Service; Associate Attending Physician, Thoracic Oncology Service; Memorial Sloan Kettering Cancer Center
12-10-2011 23:21:19
170 Tweets
4,2K Followers
225 Following
A call for rational type II TKI development. Seen through the lens of next-gen TRK inhibitor resistance in TRK fusion+ cancers. 🤓Highlights the utility of TKI type switching as a strategy for on-target resistance in oncogene-driven tumors. Emiliano Cocco Maurizio Scaltriti